SSY Group Secures NMPA Registration for Nemonoxacin Malate Bulk Drug

Bulletin Express10-29

On 29 October 2026, SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has approved the registration of Nemonoxacin Malate as a bulk drug for market-ready preparations.

The newly approved active pharmaceutical ingredient is an anti-infective agent indicated for adult community-acquired pneumonia caused by a broad spectrum of susceptible pathogens, including Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila.

The approval strengthens SSY Group’s respiratory anti-infective portfolio and marks another milestone in its product development pipeline. The Board views the decision as a significant step in expanding the company’s presence in China’s pharmaceutical market and enhancing treatment options for community-acquired pneumonia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment